ARCHIVES

Also: NCCN Committee Reaffirms Clinical Guideline Covering Avastin for Breast Cancer Indication

This article is from The Cancer Letter archive.

Vol. 37 No. 29 | July 22, 2011

Download PDF Visit The Full Archive

Related Articles

Higher Response For Gleevec In Trial; CML Patients Allowed To Switch

January 25, 2002

House-Senate Conferees Approve $6 Million Centers Amendment to Supplemental Appropriations Bill

June 27, 1986

Drug Shortages: Institutions Report Halting Enrollment in Clinical Trials

March 22, 2013

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

April 1, 2005

ODAC Recommends Approval of Evista for Breast Cancer Risk Reduction.

July 27, 2007

EntreMed Issued U.S. Patent For Active Parts Of Endostatin.

March 2, 2001